Listed

Kazia Therapeutics Ltd: Form 20-F for the period ended Jun 30, 2024

Filed with the SEC on Nov 15, 2024 and accepted by EDGAR at Nov 15, 2024, 16:02 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Income tax12 months2023-07-01 to 2024-06-30−AUD 271.0kifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2023-07-01 to 2024-06-30−AUD 26.8mifrs-full:ProfitLossAttributableToOwnersOfParent
Diluted EPS12 months2023-07-01 to 2024-06-30−AUD 0.10ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2023-07-01 to 2024-06-30−AUD 0.10ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2023-07-01 to 2024-06-30−AUD 9.6mifrs-full:CashFlowsFromUsedInOperatingActivities
Cash and equivalentsAt period end2024-06-30AUD 1.7mifrs-full:CashAndCashEquivalents
Current assetsAt period end2024-06-30AUD 6.1mifrs-full:CurrentAssets
Total assetsAt period end2024-06-30AUD 21.6mifrs-full:Assets
Current liabilitiesAt period end2024-06-30AUD 25.8mifrs-full:CurrentLiabilities
Total liabilitiesAt period end2024-06-30AUD 31.6mifrs-full:Liabilities
Shareholders' equityAt period end2024-06-30−AUD 10.0mifrs-full:EquityAttributableToOwnersOfParent
Shares outstandingAt period end2024-06-30332,850,784 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001193125-24-259805. Last ingested by Listed: Nov 2, 2026, 16:21 ET. Listed shows no prices and gives no investment advice.